271247-33-7

Upstream product

• 116332-62-8 N-methoxy-N-methyl-3-trifluoromethylbenzamide 
• 14001-63-9 2-methylthio-4-methylpyrimidine 
• 200801-88-3 2-(2-Methylsulfanylpyrimidin-4-yl)-1-(3-trifluoromethylphenyl)ethanone 
• 85475-10-1 4-(2-chloroacetyl)piperidine-1-carboxylic acid benzyl ester 

Downstream Products

• 271247-36-0 (S)-3-(3-trifluoromethylphenyl)-4-[(2-α-methylbenzylamino)pyrimidin-4-yl]-6-(N-carbobenzoxypiperidin-4-yl)pyridazine 
• 271247-35-9 3-(3-trifluoromethylphenyl)-4-(2-methylsulfonylpyrimidin-4-yl)-6-(N-carbobenzoxypiperidin-4-yl)pyridazine 
• 271247-18-8 ((S)-1-Phenyl-ethyl)-{4-[6-piperidin-4-yl-3-(3-trifluoromethyl-phenyl)-pyridazin-4-yl]-pyrimidin-2-yl}-amine 
• 853730-35-5 4-[5-{2-[1-(4-fluoro-phenyl)-ethylamino]-pyrimidin-4-yl}-6-(3-trifluoromethyl-phenyl)-pyridazin-3-yl]-piperidine-1-carboxylic acid benzyl ester 
• 853730-34-4 4-[5-(2-methylamino-pyrimidin-4-yl)-6-(3-trifluoromethyl-phenyl)-pyridazin-3-yl]-piperidine-1-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase

Novel potent trisubstituted pyridazine inhibitors of p38 MAP (mitogen activated protein) kinase are described that have activity in both cell-based assays of cytokine release and animal models of rheumatoid arthritis. They demonstrated potent inhibition o

Pyridazine based inhibitors of p38 MAPK

Trisubstituted pyridazines were synthesized and evaluated as in vitro inhibitors of p38 MAPK. The most active isomers were those possessing an aryl group α and a heteroaryl group β relative to the nitrogen atom in the 2-position of the central pyridazine.

Compounds having cytokine inhibitory activity

There are disclosed compounds of formula (I) and pharmaceutically acceptable salts thereof which exhibit utility for the treatment of cytokine mediated diseases such as arthritis.